Alzamend Neuro FY26 net loss widens 94% to $8.77 million
ALZN•FY26 loss widens as expenses rise
- Alzamend Neuro posted a GAAP net loss of USD 8.77 million, widening 94% from the prior fiscal year.
- Operating loss widened 95% to USD 8.77 million as operating expenses climbed 95% to USD 8.77 million.
- Research and development expense more than doubled to USD 3.63 million, driven by clinical trial fees of USD 2.93 million.
- General and administrative costs rose 67% to USD 5.14 million on higher professional fees of USD 2.18 million, including USD 1.9 million in legal fees.
- Cash was USD 711,000 at April 30, 2026; management flagged substantial doubt about going-concern status within one year of issuance.
